Musculoskeletal oncology, also referred to as orthopedic oncology, is a highly specialised branch of orthopedic surgery. Musculoskeletal oncology is used in the treatment of sculoskeletal cancers and tumours.

Bone and soft tissue tumors are quite rare and sometimes require reconstructive surgery. Soft tissue sarcomas are more common than bone sarcomas. For 2016, the American Cancer Society estimates about 3,300 new cases for cancer of the bones and joints, and 12,310 new cases for soft tissue sarcomas.

There are three main types of bone cancers –

osteosarcoma, which arises most often in the growing ends of long bones;
chondrosarcoma, which develops in the metaphysis;
Ewing’s sarcoma.
Chondrosarcoma is more prevalent than other form of cancers and swift diagnosis and effective treatment remains a challenge for healthcare providers. Treatment with chemotherapy and radiotherapy do not remain the preferred choice of treatment in treating such type of tumor as clinical studies demonstrate no substantial improvements in the survival rate of the patients. Therefore, adequate surgical resection is the mainstay of treatment in case of chondrosarcoma. As estimated by the American Cancer Society, chondrosarcomas is more prevalent with 40% of cases developing in adults whereas less than 5% of cases occur in patients who are less than 20 years old.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1572

Radiofrequency ablation has become the standard and most preferred choice of treatment in case of osteoid osteoma, a benign bone tumor that arises from osteoblasts. However, studies demonstrates its expanded application in palliative treatment of patients with painful bone metastasis. The ability to perform less invasive procedures often allows more efficient, less painful, and more cost-effective patient care. In addition, minimally invasive techniques, such as kyphoplasty, vertebroplasty, and acetabuloplasty may provide an alternative to major reconstructive surgery for patients with metastatic disease.

Global Musculoskeletal Oncology Therapeutics Market: Drivers & Restraints

One of the prime factors driving the global musculoskeletal oncology therapeutics market includes rapidly ageing population with increasing risk of developing cancer. Patients who had prior high-dose external radiation therapy or treatment with anti-cancer drugs are at higher risk of developing osteosarcoma. However, a small number of bone cancers also develop due to heredity defects of bones; people with metal implants, which doctors sometimes use to repair fractures, are more likely to develop osteosarcoma. In case of soft tissue sarcoma, adults with heredity disorders such as retinoblastoma, tuberous sclerosis, and Werner syndrome are at a higher risk of developing this type of cancer.

Development of safe and effective treatment procedures has also bolstered the growth of the musculoskeletal oncology therapeutics market. For example, image-guided surgery systems, primarily used in joints reconstruction, have been applied to orthopedic oncology. This may prove beneficial for areas such as the pelvis, where the complex anatomy makes the functional result difficult to interpret. Also, increasing focus of orthopedic oncologists to integrate advances in the surgical techniques by collaboration with subspecialties is also expected to boost the growth of the market during the forecast period, 2016-2026.

Unwanted complications associated with the radiation therapy, such as increased risk of wound complications and of post radiation fractures is hampering the musculoskeletal oncology therapeutics market growth. Additionally, high cost associated with the treatment and lack of awareness regarding the effective treatment therapies can also pose challenges to adoption during the forecast period.

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1572

Global Musculoskeletal Oncology Therapeutics Market: Segmentation

Musculoskeletal oncology therapeutics marketis segmented on the basis of diagnosis, treatment, end-user, and geography.

By Diagnosis

X- Ray

Magnetic resonance imaging (MRI) scan

Computed tomography (CT) scan

Positron emission tomography (PET) scan

Biopsy

By Treatment

Surgery

Amputation

Limb Salvage Surgery

Reconstructive Surgery

Chemotherapy

Radiation Therapy

Immunotherapy

Targeted Therapy

By End User

Multispecialty Hospitals

Cancer Research Institutes

Diagnostic Centers

Global Musculoskeletal Oncology Therapeutics Market: Overview

In the past few years, significant advancements have been made in treatment of musculoskeletal oncology related disorders. Yet, there is an urgent need to develop more sophisticated and highly advanced techniques to best manage hard-to-treat osteosarcomas.

Rising prevalence of musculoskeletal disorders is expected to increase emphasis on developing effective treatment procedures for cancers related to bones and soft tissues. Owing to these factors, the musculoskeletal oncology therapeutics market is expected to expand at a healthy growth rate during the forecast period.

Global Musculoskeletal Oncology Therapeutics Market: Region-wise Outlook

On the basis of region presence, musculoskeletal oncology therapeuticsmarket is segmented into seven key regions: North America, Latin America, and Eastern Europe, Western Europe, and Asia pacific excluding Japan (APEJ), Japan, Middle East and Africa. Europe and North America are the largest markets for musculoskeletal oncology therapeutics, owing to increased R&D investments and high level of awareness among end-users. Asia pacific represents immense growth opportunity for musculoskeletal oncology therapeutics market, owing to high population and increase in the prevalence of cancer.

Global Musculoskeletal Oncology Therapeutics Market: Key Players

Key market players in the musculoskeletal oncology therapeutics market are Stryker Corporation, Accentus Inc., Roche Diagnostics, Amgen Inc., Novartis AG, Biogen dec, GlaxoSmithKline, Sanofi S.A., and Pfizer Inc.

Browse Full Report@ http://www.futuremarketinsights.com/reports/musculoskeletal-oncology-therapeutics-market